¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : µÚËľüÒ½´óѧ1998ÄêÃâÒßѧ£¨²©Ê¿£©
¼¶±ð: ²©Ê¿
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-01-20   

µÚËľüÒ½´óѧ1998ÄêÃâÒßѧ£¨²©Ê¿£©

µÚËľüÒ½´óѧ1998ÄêÃâÒßѧ£¨²©Ê¿£© 7|"gMw/  
#SzCd&hI   
£¨ÃâÒßѧרҵºÍרҵ»ù´¡£© h zh%ML3L  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© c%|18dV  
1.Co-stimulators (or co-stimulating molecules) W+'|zhn  
2.NK-kB .mse.$TK.^  
3.Immunoglobulin superfamily FTihxC?.L  
4.antigen-presenting cell (APC) },2mIit(  
5.death domain "Zh6j)[o  
6.CCR and CXCR %Q}T9%Mtj  
7.Lectin (or mitogen) Mpm#a0f  
8.Clusters of differentiation, CD) "0lC:Wu]  
9.B7 family N* C"+2  
10.Cytotoxic T lymphocyte, CTL) u_C/Y[ik  
11.IL-15 and IL-15 receptor (IL-15R) P(1 bd"Q  
12.MHC restriction v\Y362Xv  
13.Affinity-chromatography gCMwmanX  
14.Cyctosprin A, CsA RaS7IL:e  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) )1KlcF  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© TZT1nj"n  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 ;t.LLd  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ =]pcC  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢á¹¹¼°Æäʶ±?¿¹Ô­µÄÌØµã¡£ .,C8ASfh  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© 9` /\|t|V  
ÃâÒßѧרҵ£º Lh%>> Ht{  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ "g)@jqq:>  
Ïû»¯ÄÚ¿Æ£º 6$}hb|j  
2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ / $7_*4e  
ѪҺ²¡Ñ§×¨Òµ£º ?lh `>v  
3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
Ãâ·Ñ¿¼²©ÂÛÌ³ÍøÖ·ÊÇʲô? ÕýÈ·´ð°¸:freekaobo.com
°´"Ctrl+Enter"Ö±½ÓÌá½»